Immuneering (IMRX) Cash & Equivalents (2020 - 2026)

Immuneering's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 31.94% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 31.94% YoY), while the FY2025 annual figure was $128.6 million, up 255.92% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $47.3 million, down from $128.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $227.6 million in Q3 2025, with the low at $26.4 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $68.0 million (2023), against an average of $76.1 million.
• Peak annual rise in Cash & Equivalents reached 403.4% in 2025, while the deepest fall reached 55.87% in 2025.
• Immuneering's Cash & Equivalents stood at $72.6 million in 2022, then slipped by 18.22% to $59.4 million in 2023, then sank by 39.16% to $36.1 million in 2024, then surged by 255.92% to $128.6 million in 2025, then tumbled by 63.22% to $47.3 million in 2026.
• Business Quant data shows IMRX's Cash & Equivalents at $47.3 million in Q1 2026, $128.6 million in Q4 2025, and $227.6 million in Q3 2025.